BioWorld Asia

Dec. 22, 2010

View Archived Issues

EpiTherapeutics, Abbott in Epigenetics Oncology Deal

EpiTherapeutics ApS, which is developing cancer drugs based on epigenetics targets, entered its first drug discovery pact, with Abbott, of Abbott Park, Ill. (BioWorld International) Read More

Xention Spins Out Provesica to Advance Bladder Drug

Read More

Genomics of Lung Cancer Yields a New Drug Target

Read More

NovImmune Tops Off Cash with $20M for Antibody Trials

Read More

Two Biotechs Merge to Form PsiOxus Therapeutics

Read More

Proximagen Picks up GSK's Discarded CNS Programs

Read More

Other News To Note

Read More